• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Cleveland Clinic–led study shows potential benefits of ultrasound-guided prostate SBRT

News
Article

The published findings show the viability of using a transperineal ultrasound system as a means to monitor intra-fractional prostate motion for prostate stereotactic body radiotherapy.

Research led by a team of Cleveland Clinic experts demonstrates the feasibility and clinical efficiency of ultrasound-guided prostate stereotactic body radiation therapy using a 4D transperineal ultrasound system.

“Our study not only demonstrates the feasibility of ultrasound-guided prostate SBRT, but also shows that it fits into our standard SBRT workflow,” said first author Bingqi Guo, PhD, department of Radiation Oncology at Taussig Cancer Center, Cleveland Clinic. “The presence of an ultrasound probe did not compromise the contouring of targets or critical structures.”

“Our study not only demonstrates the feasibility of ultrasound-guided prostate SBRT, but also shows that it fits into our standard SBRT workflow,” said first author Bingqi Guo, PhD, department of Radiation Oncology at Taussig Cancer Center, Cleveland Clinic. “The presence of an ultrasound probe did not compromise the contouring of targets or critical structures.”

These findings,1 which were recently published in the Journal of Applied Clinical Medical Physics, suggest that real-time intra-fraction motion management could help improve delivery accuracy for prostate stereotactic body radiotherapy.

“Ultra-hypofractionated stereotactic body radiotherapy for prostate cancer is an emerging treatment approach for low/intermediate-risk prostate cancer,” says first author Bingqi Guo, PhD, Department of Radiation Oncology at Taussig Cancer Center, Cleveland Clinic. “Given the high precision nature of this treatment, it is important that the prostate stays in the same position.

“One way this is accomplished is with the use of fiducial markers; however, this is invasive and not a suitable option for all patients,” she continues. “In our study, we sought to better understand the potential of ultrasound-guided prostate SBRT, particularly for patients who would benefit from a more non-invasive approach.”

In this prospective study, Dr. Guo and her colleagues highlight their clinical experience using a transperineal ultrasound system as a means to monitor intra-fractional prostate motion for prostate stereotactic body radiotherapy (SBRT).

The analysis included 23 SBRT patients who were treated at the Cleveland Clinic between April 2016 and November 2019. Eligible patients were adults with an established diagnosis of prostate cancer who were proceeding with definitive radiation. They had a performance status of Karnofsky PS ≥ 70.

Design and methods

The research team used the following prescription doses: 36.25 Gy to the low-dose planning target volume and 40 Gy to the high-dose planning target volume in five fractions with three mm planning margins.

“For intra-fraction prostate motion, the real-time prostate displacements measured by ultrasound were exported for analysis,” according to Dr. Guo and her colleagues. “The percentage of time prostate movement exceeded a two mm threshold was calculated for each fraction of all patients. T-test was used for all statistical comparisons.”

Key takeaways

Dr. Guo and her colleagues successfully used the transperineal ultrasound system on all 23 prostate SBRT patients and in 110 of the 115 treatment fractions for intra-fraction motion monitoring. “For the five fractions in which patients were treated without ultrasound monitoring, the probe remained in the same position as CT simulation to maintain the same anatomy.”

Data confirmed that the ultrasound image quality was sufficient for visualization of the prostate and surrounding organs at risk. The setup time for each fraction under ultrasound-guided prostate SBRT was 15.0 ± 4.9 minutes. The total treatment time per fraction was 31.8 ± 10.5 minutes.

“Our study not only demonstrates the feasibility of ultrasound-guided prostate SBRT, but also shows that it fits into our standard SBRT workflow,” says Dr. Guo. “The presence of an ultrasound probe did not compromise the contouring of targets or critical structures.”

The researchers monitored prostate intra-fraction motion throughout the entire treatment; however, they only analyzed motion after kilo-voltage cone beam computed tomography (KV-CBCT) and before the delivery completion.

A warning was triggered when prostate movements were more than 2 mm in any direction. This prompted clinicians to manually hold the beam until the prostate position returned back to within 2 mm threshold.

When discussing intro-fraction motion, Dr. Guo notes that prostate movement exceeded 2 mm tolerance in 23 of 110 fractions for 11 of 23 patients. “For all fractions, the mean percentage of time when the prostate moved more than 2 mm in any direction during each fraction was 7%, ranging from 0% to 62% of a fraction.”

Based on the researchers’ experience, the procedure was well-tolerated by patients. Additionally, the training for therapists is minimal and straightforward.

“This analysis suggests that ultrasound-guided prostate stereotactic body radiation therapy is an effective, non-invasive alternative for patients who cannot tolerate marker/spacer implantation or have other contraindications. The next step is to further simply and streamline the process to benefit even more patients.”

Reference

1. Guo B, Stephans K, Godley A, et al. Transperineal ultrasound is a good alternative for intra-fraction motion monitoring for prostate stereotactic body radiotherapy [published online ahead of print May 5, 2023]. J Appl Clin Med. doi: 10.1002/acm2.14021

Related Videos
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
Female doctor talking with male patient | Image Credit: © Prostock-studio - stock.adobe.com
Daniel A. Triner, MD, PhD, answers a question during a Zoom video interview
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.